liver cancer
Conditions
Interventions
Experimental group:Atelizumab, bevacizumab combined with Huaier granules
Control group:Atelizumab, bevacizumab
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years, regardless of gender; 2. The diagnosis of HCC is confirmed by imaging examination, serum alpha-fetoprotein (AFP) examination or pathology, and cannot accept surgical resection; 3. According to the modified solid tumor efficacy evaluation criteria (mRECIST), there is at least one target lesion that can be evaluated; 4. Karnofsky (KPS) score >= 60 points; 5. Child-Pugh score of liver function = 12 weeks; 7. Have not received chemotherapy, immunotherapy, targeted therapy and other systemic treatment methods before enrollment or during the study period; 8. Patients and their families are willing to cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating women; 2. Cannot tolerate Chinese medicine; 3. Patients who refuse to participate or withdraw from the study halfway through.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood routine;Liver function;Kidney function;Alpha-fetoprotein;Abdominal CT; | — |
Countries
China
Contacts
Public ContactTian Weijun
Tianjin Medical University General Hospital
Outcome results
None listed